These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34837495)

  • 1. Placebo control group in COVID-19 vaccine trials: context and timing matters.
    Dal-Ré R
    Eur J Clin Pharmacol; 2022 Mar; 78(3):523-526. PubMed ID: 34837495
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 vaccine trials: The potential for "hybrid" analyses.
    Fleming TR; Nason M; Krause PR; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Aug; 18(4):391-397. PubMed ID: 34041932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled trials with COVID-19 vaccines: participants first.
    Dal-Ré R
    J Clin Epidemiol; 2021 Oct; 138():211-212. PubMed ID: 34271109
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.
    Joffe S
    JAMA; 2021 Jan; 325(3):221-222. PubMed ID: 33315069
    [No Abstract]   [Full Text] [Related]  

  • 5. Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical?
    Dal-Ré R; Caplan AL
    Clin Microbiol Infect; 2021 Nov; 27(11):1565-1567. PubMed ID: 34375757
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
    Sisa I; Noblecilla E; Orozco F
    Lancet; 2021 Mar; 397(10277):878. PubMed ID: 33617776
    [No Abstract]   [Full Text] [Related]  

  • 9. Placebo-controlled trials of Covid-19 vaccines - Are they still ethical?
    Ortiz-Millán G
    Indian J Med Ethics; 2021; VI(2):1-8. PubMed ID: 33908358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo in new Covid-19 vaccine trials: data quality prioritised over participants' rights.
    Srinivasan S
    Indian J Med Ethics; 2021; VI(2):1-6. PubMed ID: 33908351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "No" to placebo-controlled trials of Covid-19 vaccines.
    Ahmad A; Dhrolia MF
    Indian J Med Ethics; 2021; VI(2):1-7. PubMed ID: 33908356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo use in vaccine trials: recommendations of a WHO expert panel.
    Rid A; Saxena A; Baqui AH; Bhan A; Bines J; Bouesseau MC; Caplan A; Colgrove J; Dhai A; Gomez-Diaz R; Green SK; Kang G; Lagos R; Loh P; London AJ; Mulholland K; Neels P; Pitisuttithum P; Sarr SC; Selgelid M; Sheehan M; Smith PG
    Vaccine; 2014 Aug; 32(37):4708-12. PubMed ID: 24768580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Problematic Covid-19 vaccine trials in times of vaccine nationalism.
    Ravinetto R
    Indian J Med Ethics; 2021; VI(2):1-7. PubMed ID: 33908359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccine trial ethics once we have efficacious vaccines.
    Wendler D; Ochoa J; Millum J; Grady C; Taylor HA
    Science; 2020 Dec; 370(6522):1277-1279. PubMed ID: 33273060
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.
    Mehrotra DV; Janes HE; Fleming TR; Annunziato PW; Neuzil KM; Carpp LN; Benkeser D; Brown ER; Carone M; Cho I; Donnell D; Fay MP; Fong Y; Han S; Hirsch I; Huang Y; Huang Y; Hyrien O; Juraska M; Luedtke A; Nason M; Vandebosch A; Zhou H; Cohen MS; Corey L; Hartzel J; Follmann D; Gilbert PB
    Ann Intern Med; 2021 Feb; 174(2):221-228. PubMed ID: 33090877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing vaccines in the time of Covid: The changing landscape.
    Cash RA
    Indian J Med Ethics; 2021; VI(2):1-4. PubMed ID: 33908357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trials for second generation Covid-19 vaccines: Revisiting the debate over placebo use in developing country clinical trials.
    Lurie P
    Indian J Med Ethics; 2021; VI(2):1-10. PubMed ID: 33908352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis.
    Haas JW; Bender FL; Ballou S; Kelley JM; Wilhelm M; Miller FG; Rief W; Kaptchuk TJ
    JAMA Netw Open; 2022 Jan; 5(1):e2143955. PubMed ID: 35040967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo control in Covid-19 trials: A missed opportunity for international guidance.
    Wiesing U; Ehni HJ
    Indian J Med Ethics; 2021; VI(2):1-7. PubMed ID: 33908353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.